ライフサイエンスコーパス: ablative

1 , biochemically active, and was not androgen ablative.

2 This study examines the outcomes of ablative (131)I therapy after diagnostic studies with ei

3 d tumor characteristics and received similar ablative activities of (131)I.

4 AR repression, as evidenced by the higher AR-ablative activity of the permuted isomer 9 [( Z)-5-(4-hy

5 ral prostate (PC-3) tumors with the vascular ablative agent VEGF(121)/recombinant gelonin (rGel) stro

6 provides a proof of principle that potent AR-ablative agents could be developed through structural mo

7 optimization to develop a novel class of AR-ablative agents.

8 affold to develop a novel class of cyclin D1-ablative agents.

9 use troglitazone as a platform to design AR-ablative agents.

10 sms of prostate cancer resistance to hormone-ablative and anti-androgen therapy.

11 (CIN) is common, and current treatments are ablative and can lead to long-term reproductive morbidit

12 Ablative and chronic stimulation procedures targeting th

13 With increasing experience, advanced ablative and complex reconstructive procedures are now b

14 surgery, laser hair removal, and fractional ablative and nonablative laser procedures for patients c

15 ify areas under active investigation in both ablative and nonmyeloablative unrelated-donor stem cell

16 well tolerated, feasible, and effective for ablative and reconstructive indications with minimal com

17 common postoperative complication following ablative and reconstructive surgeries, in an animal mode

18 With current medical, ablative, and device therapies, the majority of patients

19 The patient was homozygous for an ablative APOE frameshift mutation (c.291del, p.E97fs).

20 ation of an anatomically guided slow pathway ablative approach and emphasize the importance of detail

21 o facilitate developing a focused, strategic ablative approach at the onset of a procedure.

22 rom atrial tachyarrhythmias between an index ablative approach of stand-alone PVI and a stepwise appr

23 Image-guided transcatheter and ablative approaches currently play an important role in

24 Many ablative approaches in or near the orifice of the pulmon

25 erly or comorbid patients, it is likely that ablative approaches will assume an increasingly central

26 vertebroplasty, and minimally invasive local ablative approaches.

27 Ablative BMT in neonatal mice with or without the lysoso

28 Dormant tumor cells resistant to ablative cancer therapy represent a significant clinical

29 c resurfacing procedures, specifically fully ablative carbon dioxide laser or medium-depth chemical p

30 lity, safety, and treatment effectiveness of ablative chemoembolization (ACE) in the treatment of hep

31 Reported is an animal model of ablative CKD complicated by an ABD characterized by the

32 e disappearance of gene-modified cells after ablative conditioning may be due to an immune response.

33 though we previously reported that partially ablative conditioning with 700 cGy of total body irradia

34 rimary and secondary hosts in the absence of ablative conditioning.

35 rate, primarily from complications of marrow-ablative conditioning.

36 The immune ablative (conditioning) regimen consisted of 200 mg/kg c

37 These results suggest that ablative control of the primary tumor may prolong surviv

38 p to one year after treatment were seen with ablative devices (27.8% vs. 26.1%, OR 1.09 [95% CI 0.99

39 (6,958 patients) were not improved with the ablative devices (38.9% vs. 37.4%, OR 1.06 [95% CI 0.97

40 erience from randomized trials suggests that ablative devices failed to achieve predefined clinical a

41 tal role in the +-application of these probe ablative devices.

42 All this serves to allow the delivery of ablative dose fractionation to the target capable of bot

43 A BED greater than 80.5 Gy seems to be an ablative dose of RT for large IHCCs, with long-term surv

44 uses advanced technology to deliver a potent ablative dose to deep-seated tumors in the lung, liver,

45 Although mechanisms of ablative-dose injury remain elusive, ongoing prospective

46 -guided radiotherapy, now allows delivery of ablative doses of radiation to extracranial sites.

47 dvances allow safe and effective delivery of ablative doses of radiation with stereotactic precision

48 ) techniques and image guidance have enabled ablative doses to be delivered to large liver tumors.

49 By providing an ablative effect noninvasively, SRS has altered the treat

50 Methylprednisolone injections are a non-ablative, effective treatment for refractory Meniere's d

51 993113 effectively inhibited the bone marrow ablative effects of 7,12-dimethylbenz[a]anthracene in vi

52 cant differences in QoL improvement across 3 ablative efficacy outcomes.

53 symptom assessment more accurately reflects ablative efficacy.

54 is a strong predictor of ostial sites where ablative energy is required to electrically isolate the

55 The development of ablative energy sources has simplified the surgical trea

56 lability of improved ureteroscopes and newer ablative energy sources, endoscopic management of upper

57 sponsiveness, although the effect may not be ablative even in the presence of exogenous agonist.

58 We show here that a safer ablative fractional laser (AFL) can sufficiently facilit

59 asive pads, microneedling with dermarollers, ablative fractional laser (AFXL), non-AFXL, and no pretr

60 is briefly illuminated with a handheld, non-ablative fractional laser before the vaccine is intrader

61 EPD is based on ablative fractional laser or microneedle treatment of th

62 sis and marked shift in collagen types after ablative fractional laser resurfacing (AFR) within treat

63 ion of powder drug-coated array patches onto ablative fractional laser-generated skin MCs to deliver

64 Currently ablative fractional photothermolysis (aFP) with CO2 lase

65 The advent of ablative fractional photothermolysis within the past dec

66 sensus is that laser treatment, particularly ablative fractional resurfacing, deserves a prominent ro

67 a result of the unique biologic response to ablative fractionation.

68 Compared with traditional ablative HIFU, nondestructive pulsed HIFU (pHIFU) is pre

69 erwent nonablative HSCT and 52 who underwent ablative HSCT (median ages, 56 and 54 years, respectivel

70 nation of nonablative low-energy FUS with an ablative hypofractionated radiation therapy results in s

71 assist in the development of techniques for ablative intervention.

72 dy testing the noninferiority of survival of ablative intravenous busulfan (IV-BU) vs ablative total

73 ssess whether survival of patients receiving ablative intravenous busulfan-based conditioning regimen

74 iterature, mechanical dermabrasion and fully ablative laser are not recommended in the setting of sys

75 Ablative laser photocoagulation is indicated for very se

76 Solutions include switching to ablative laser prostatectomy (which may carry higher lon

77 Laser scar therapy, particularly fractional ablative laser resurfacing, represents a promising and v

78 stin may be recommended without the need for ablative LASER therapy and before retinal detachment dev

79 o those published for a series of fractional ablative laser treatments.

80 or RCM imaging, which, when combined with an ablative laser, may one day provide an efficient and cos

81 inoids, acitretin, surgery, surgical, laser, ablative laser, nonablative laser, laser hair removal, c

82 to the blood (A(max)), and the corresponding ablative lesion dose (D(lesion)).

83 rt disease may be achieved by creation of an ablative lesion in a critical isthmus of conduction boun

84 yoballoon for small PVs, but showed narrower ablative lesions in the left atrial antrum.

85 Histologically, deeper extensions of ablative lesions into the PV were seen with 23-mm cryoba

86 flutter, and 2) characterize the effects of ablative lesions on the properties of isthmus conduction

87 we sought to assess if the use of additional ablative lesions that targeted all potential re-entrant

88 were seen with 23-mm cryoballoon, and larger ablative lesions were seen in the left atrial antrum usi

89 ally occurring genetic mutations, as well as ablative lesions, have shown that the brain regulates bo

90 st likely rely on creating transmural linear ablative lesions.

91 are usually self-limited, and correlate with ablative margin volume--except for changes in platelet c

92 dure were analyzed with respect to tumor and ablative margin volumes by using generalized estimating

93 Ablative margin volumes were predictive of changes at 0-

94 The mean ablative margin was 1.7 cm, and only one of nine cases,

95 r treatment of large tumors and achieving an ablative margin within the untreated tissue surrounding

96 Cryoablation is the most evaluated probe ablative method for the treatment of small renal masses.

97 l, IRE proved to be a fast, safe, and potent ablative method, causing complete tissue death by means

98 hundred forty-three patients were treated by ablative methods.

99 udies show success rates comparable to other ablative modalities for the treatment of Barrett's esoph

100 The integration of surgery or ablative modalities is often employed, particularly when

101 The specific ablative modalities of radiofrequency ablation, microwav

102 c, and immunologic responses between the two ablative modalities.

103 inct when compared with conventional thermal ablative modalities.

104 ta addressing the oncologic efficacy of this ablative modality are now available.

105 scopic spray cryotherapy is a relatively new ablative modality for the treatment of gastrointestinal

106 Endoscopic spray cryotherapy is a promising ablative modality for treatment of Barrett's esophagus a

107 The phospho-ablative mutation S344A did not have significant effect

108 Preparative regimens were ablative (n = 7) and nonablative (n = 3).

109 ain stimulation (DBS) has virtually replaced ablative neurosurgery for use in medication-refractory m

110 cervical intraepithelial neoplasia (CIN) by ablative or excisional techniques is widely used.

111 dysplastic areas, (3) patients that receive ablative or surgical therapy require endoscopic follow-u

112 % in nonablative patients compared to 32% in ablative patients (hazard ratio=1.4).

113 loablative patients were at higher risk than ablative patients because of greater age, longer time fr

114 e patients given myeloablative conditioning (ablative patients) before unrelated HCT.

115 enced fewer grades III to IV toxicities than ablative patients.

116 a less painful rectal procedure in place of ablative perianal surgery.

117 of focused high-intensity light sources for ablative perturbation has been an important technique fo

118 , including the time required for the breast ablative portion of the procedures, was 8.6 hours.

119 nd nervous tissue, albeit with somewhat less ablative potency.

120 Having undergone a previous ablative procedure did not lessen a patient's likelihood

121 imilarity of serum creatinines 3 d after the ablative procedure.

122 s (<31 days) were not improved by the use of ablative procedures (0.3% vs. 0.4%, odds ratio [OR] 0.94

123 r nonhealing facial erosions occurring after ablative procedures (carbon dioxide laser resurfacing or

124 e performed at least 6 months after lamellar ablative procedures and at least 3 months after surface

125 ld provide real-time guidance during complex ablative procedures and may provide an efficient techniq

126 is the most studied of all the energy based ablative procedures and shows considerable promise.

127 Ablative procedures can provide substantial clinical ben

128 eater utilization of partial nephrectomy and ablative procedures has increased the incidence of patie

129 Energy based ablative procedures have triggered considerable interest

130 These ablative procedures may provoke the deterioration of adj

131 document highlights that, while stereotactic ablative procedures such as cingulotomy and capsulotomy

132 rpative laparoscopic partial nephrectomy and ablative procedures such as cryoablation, radiofrequency

133 ce of side-effects associated with bilateral ablative procedures, alternative approaches were explore

134 atients who have nonhealing wounds following ablative procedures, EPD is challenging to treat and may

135 ocedures and at least 3 months after surface ablative procedures.

136 cosae, cautioning against the use of mucosal ablative procedures.

137 hnique could improve the success rate of the ablative procedures.

138 ts support the hypothesis that the favorable ablative properties of protein-targeting wavelengths res

139 accumulated in humans regarding stereotactic ablative radiation (SABR) therapy, a favorable option fo

140 was produced in a mouse-->rat model by using ablative radiation and a high dose of donor cells.

141 adiation therapy (SBRT) is generally a tumor-ablative radiation modality using essential technologies

142 Recent studies have shown that local ablative radiation of established tumors can lead to inc

143 ch extrinsic resistance develops after local ablative radiation that relies on the immunosuppressive

144 es in 101 patients treated with stereotactic ablative radiation therapy from 2005 to 2013 were analyz

145 ly cured by surgery alone or surgery plus an ablative radiation therapy.

146 imaging and noninvasive delivery of precise ablative radiation with stereotactic body radiation ther

147 patients with thyroid carcinoma at the first ablative radioiodine therapy.

148 onale and clinical data for both sterotactic ablative radiotherapy (SABR) and targeted therapies, and

149 Stereotactic ablative radiotherapy (SABR) for inoperable stage I NSCL

150 bectomy, sublobar resection, or stereotactic ablative radiotherapy (SABR) from January 1, 2003, throu

151 pare organs at risk (OARs) when stereotactic ablative radiotherapy (SABR) is delivered to treat centr

152 The application of stereotactic ablative radiotherapy (SABR) to hepatocellular carcinoma

153 ed to predict the response to incisional and ablative refractive surgery and will also affect the for

154 153 patients underwent ABMT using a uniform ablative regimen with cyclophosphamide and total body ir

155 The ablative regimens included: (1) thiotepa (TT)/cyclophosp

156 To improve autografting, better ablative regimens, more efficacious purging of tumor cel

157 report that reduction of tumor burden after ablative RT depends largely on T-cell responses.

158 Ablative RT dramatically increases T-cell priming in dra

159 We show that ablative RT increases intratumoral production of IFN-bet

160 We further demonstrate that ablative RT-initiated immune responses and tumor reducti

161 echnology allow for the use of high-dose (or ablative) RT to target local tumors, with limited damage

162 In the 1960s, ablative stereotactic surgery was employed for a variety

163 ssing the benefits of de-novo ICD placement, ablative strategies and other prophylactic and therapeut

164 atrial fibrillation, the outcomes of initial ablative strategies comprising either stand-alone PVI (P

165 ng, biomarkers, pharmacological therapy, and ablative strategies for AF.

166 e important implications for both pacing and ablative strategies for the prevention of initiation of

167 The addition of ablative superficial venous surgery to this strategy has

168 ts requiring midface reconstruction have had ablative surgery for malignant disease, and most require

169 obotic-assisted, ureteral reconstructive and ablative surgery is being performed routinely for both b

170 mammary gland development without resort to ablative surgery of the endocrine glands.

171 iltrative endometriosis undergoing CO2 laser ablative surgery with bowel resection (study group, 76/2

172 atment of glaucoma patients undergoing laser ablative surgery, and makes recommendations to improve c

173 d consenting women, referred for endometrial ablative surgery, were randomly assigned MEA (Microsulis

174 Advances in minimally invasive ablative surgical approaches have led to the development

175 ot inferior to that of patients receiving an ablative TBI-based regimen.

176 Radiofrequency ablation is the best ablative technique for the treatment of small hepatocell

177 technical considerations for this particular ablative technique.

178 Current surgical therapies include ablative techniques (thalamotomy and pallidotomy), augme

179 Apart from extirpative treatment, ablative techniques are becoming more popular to minimiz

180 rd diagnosis of smaller renal masses, energy ablative techniques are being increasingly utilized as p

181 Results obtained with energy ablative techniques are encouraging.

182 Energy-based tumor ablative techniques are under development for the minima

183 ts related to the modern surgical and energy ablative techniques for renal cell carcinoma.

184 Ablative techniques include pallidotomy, thalamotomy, an

185 Oncological effectiveness of ablative techniques is encouraging as 3-year data are em

186 l, largely because thermal and photochemical ablative techniques often leave foci of intestinal metap

187 culprit arrhythmia using pharmacological or ablative techniques result in symptom resolution and rec

188 These ablative techniques should be reserved for carefully sel

189 ith contraindications to other commonly used ablative techniques.

190 of the PVs and can be effectively treated by ablative techniques.

191 rcinoma (HCC) who are ineligible for thermal ablative techniques.

192 aging program that offers both resection and ablative techniques.

193 -term (5 years and greater) outcome data for ablative technologies accumulate, we are likely to see a

194 roscopic and percutaneous minimally invasive ablative technologies are being increasingly employed in

195 Encouraging long-term data for ablative technologies are emerging.

196 the basis of these studies, it is clear that ablative technologies can be effective treatments for se

197 Advances in surgical and ablative technologies have contributed to a decrease in

198 Several energy ablative technologies, currently being tested in clinica

199 cancers has led to the development of energy ablative technologies, which are less invasive alternati

200 Laser powers of 3 and 6W achieved ablative temperatures of more than 50 degrees C.

201 e in tumor temperature, from 37 degrees C to ablative temperatures of more than 50 degrees C.

202 al approach with drug-eluting microspheres), ablative therapies (such as chemical [ethanol or acetic

203 anol or acetic acid injection]), and thermal ablative therapies (such as radiofrequency ablation, las

204 acteristics and, as outcomes data mature, to ablative therapies and active surveillance.

205 HIFU is often used for ablative therapies and must be adapted to produce unifor

206 for small renal masses confirmed malignant, ablative therapies are an option in elderly patients, wh

207 e cancer survivors treated with radiation or ablative therapies are at risk for urethral stricture fo

208 an be continued beyond progression and local ablative therapies can be used to target sites of oligop

209 Locoregional transcatheter and ablative therapies continue to be used mostly for pallia

210 Elimination of B-cell ablative therapies did not result in an increased incide

211 Ablative therapies extend the capability of delivering p

212 lamic nucleus (STN-DBS) has largely replaced ablative therapies for Parkinson's disease.

213 ancer, the most interesting findings concern ablative therapies for primary and recurrent prostate ca

214 t widely used locoregional transcatheter and ablative therapies for solid malignancies.

215 Ablative therapies have been increasingly utilized in th

216 her innovative, relatively noninvasive local ablative therapies have been introduced and have been sh

217 Ablative therapies may lead to buried metaplasia in a sm

218 nterpreting the short-term results of energy ablative therapies monitored by imaging only.

219 Endoscopic surveillance after any of the ablative therapies still appears to be necessary.

220 mpatible kidney transplantation using B-cell ablative therapies such as anti-CD20 and splenectomy.

221 resection, liver transplantation, and local ablative therapies such as radio frequency ablation offe

222 resection, liver transplantation, and local ablative therapies such as radiofrequency ablation offer

223 linical and clinical trials to develop tumor ablative therapies that use viral, yeast, or bacterial g

224 Ablative therapies, as well as endoscopic mucosal resect

225 cell pool in patients recovering from T cell ablative therapies, HIV patients under highly active ant

226 o improve the efficacy and/or specificity of ablative therapies.

227 ssion and potentiate the effects of standard ablative therapies.

228 ikely to be candidates for surgical or local ablative therapies.

229 and bladder neck contractures resulting from ablative therapies.

230 nd may participate in resistance to androgen-ablative therapies.

231 ver resection (HR, 0.38; 95% CI, 0.28-0.52), ablative therapy (HR, 0.63; 95% CI, 0.52-0.76), and tran

232 ined before ablative therapy, 30 pairs after ablative therapy and 15 pairs after 131I therapy for met

233 Despite the current success of ablative therapy and implantable defibrillators, the nee

234 prostate cancer patients undergoing androgen ablative therapy and mediates growth of androgen-insensi

235 ed interest recently in the use of high dose ablative therapy and stem cell support.

236 ieve either rate or rhythm control, curative ablative therapy directed at the underlying tachycardia

237 assessment of this technology as a potential ablative therapy for a number of organs and disease proc

238 an application of this technology to thermal ablative therapy for cancer is described.

239 t loss of dysplasia in patients treated with ablative therapy for HGD/intramucosal cancer.

240 investigating the optimal timing of androgen ablative therapy for prostate cancer.

241 Catheter ablative therapy for the arrhythmias attempted in the ve

242 ough initial treatment strategies focused on ablative therapy for threshold ROP, earlier treatment fo

243 ue to identify atrial reentrant circuits for ablative therapy guidance.

244 ment of biologically indolent cancers, focal ablative therapy has been introduced as an alternative t

245 Percutaneous local ablative therapy has proved very effective.

246 en an explosion in the literature describing ablative therapy in Barrett's esophagus.

247 timing and patient selection for endoscopic ablative therapy in Barrett's esophagus.

248 ectroanatomic characteristics and outcome of ablative therapy in consecutive patients with (1) RV dil

249 The role of ablative therapy in patients with MVR is not yet establi

250 a rationale for a systematic study on B-cell ablative therapy in patients with sarcoidosis.

251 We demonstrate that androgen ablative therapy induces profuse T cell infiltration of

252 igorous follow-up of all patients undergoing ablative therapy is required.

253 ico definition, active surveillance or focal ablative therapy may be a rational alternative to surgic

254 Endoscopic ablative therapy may provide clinicians an attractive al

255 casionally be identified, and (3) aggressive ablative therapy provides long-term VT control.

256 cm and no extension beyond the liver, use of ablative therapy significantly increased during 2000-201

257 The longest-term outcomes of probe-ablative therapy with cryoablation and radiofrequency ab

258 Each trial tested the hypothesis that ablative therapy would result in better clinical or angi

259 n to HG-IEN/BAc, and strict surveillance (or ablative therapy) is advisable in cases with endoscopic

260 ifteen pairs of studies were obtained before ablative therapy, 30 pairs after ablative therapy and 15

261 In 105 patients, PVI was the sole ablative therapy, 49 (46.7%) of those patients remained

262 d angiography/embolization, resection, local ablative therapy, and liver transplantation.

263 ablation are the two most utilized forms of ablative therapy, and the most mature.

264 ular cancer after hepatic resection or local ablative therapy, compared with controls, participants r

265 h Barrett's esophagus-related LGD undergoing ablative therapy, radiofrequency ablation should be used

266 alignancy and responds initially to androgen ablative therapy.

267 g and preemptive intervention by surgical or ablative therapy.

268 h Barrett's esophagus, both before and after ablative therapy.

269 recurrence after hepatic resection or local ablative therapy.

270 imaging, image-guidance systems, catheters, ablative tools, and drug delivery systems.

271 After marrow ablative total body irradiation (920 cGy), prompt hemato

272 of ablative intravenous busulfan (IV-BU) vs ablative total body irradiation (TBI)-based regimens in

273 e older, and had more often failed preceding ablative transplantations and cytotoxic therapies, they

274 derwent intraoperative RetCam FA and retinal ablative treatment and who had more than 3 months of fol

275 The role of pulmonary vein (PV) isolation in ablative treatment of atrial fibrillation (AF) has been

276 t 15 years have greatly improved outcomes in ablative treatment of tachyarrhythmias in children.

277 l or unilateral prostate cancer, a number of ablative treatment options for focal therapy are availab

278 lateral prostate cancer lesions, a number of ablative treatment options for focal therapy are availab

279 However, the results of commonly performed ablative treatments (cholecystectomy and sphincterotomy)

280 We review recent literature regarding focal ablative treatments of SRMs.

281 Local ablative treatments such as ethanol injection can length

282 tomographic imaging, and (3) the efficacy of ablative treatments that result in the curative depletio

283 Needle and probe-based ablative treatments will continue to play an important r

284 Ablative treatments, including Nd:YAG laser, photodynami

285 er survivors who have undergone radiation or ablative treatments.